Clinical trial
Durvalumab (MEDI4736) as Maintenance Treatment Following Chemoradiation for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (DESC).
NCT04054518 is registered in ClinicalTrials.gov with Tiago Biachi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Durvalumab (MEDI4736) as Maintenance Treatment Following Chemoradiation for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (DESC).
- Lead sponsor
- Tiago Biachi
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 1, 2019
- Completion date
- October 1, 2022
- Enrollment
- 22 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.